Maternal mRNA COVID-19 vaccination shields infants for six months

Women who receive an mRNA-based COVID-19 vaccination or booster during pregnancy can provide their infants with strong protection against symptomatic COVID-19 infection for at least six months after birth, according to a study from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

FDA offers suite of new guidance on AI, accelerated approvals, clinical trials and more

With two weeks until President-elect Donald Trump’s administration takes over, the FDA on Monday released dozens of new draft and final guidance documents covering everything

January 7, 2025

Eye Drop Company in FDA’s Sights Once Again

The FDA has sent another letter — this time a warning letter — to a company that it previously flagged for marketing amniotic fluid eye

September 18, 2024

EASD 2024: Novel insights into maternal protection in T1D – Pharmaceutical Technology

At the European Association for the Study of Diabetes (EASD) 2024 conference, results were presented for a meta-analysis, shedding new light on the genetic transmission

September 10, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.